Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa ...

ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Zevaskyn™ Approved by FDA On April 29, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

The US Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also ...

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN gene-modified cellular sheets.

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene ...

The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Zevaskyn ...